Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-12
- Development stage
- Preclinical
- Lead developer
- Next Innovative Therapeutics
01
Overview
NTX-12 is an early-stage therapeutic candidate being developed by Next Innovative Therapeutics (Nintx) for the treatment of psoriasis. Discovered using the company's proprietary GAIApath® and xGIbiomics® platforms, which combine biodiversity, artificial intelligence, and microbiome science, NTX-12 is designed to modulate biological pathways involved in chronic inflammation. The drug is currently in the discovery phase of development.
Beyond the preview
Go deeper on NTX-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-12.